This Article Full Text Full Text (PDF) All Versions of this Article: 33/12/3030    most recent 01.STR.0000037674.95228.86v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lampl, C. Articles by Röper, C. Search for Related Content PubMed PubMed Citation Articles by Lampl, C. Articles by Röper, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMITRIPTYLINE Medline Plus Health Information Pain Pain Relievers Stroke Related Collections Acute Cerebral Infarction Rehabilitation, Stroke Other Stroke Treatment - Medical Other Research

(Stroke. 2002;33:3030.)
© 2002 American Heart Association, Inc.

Research Report

Amitriptyline in the Prophylaxis of Central Poststroke Pain

Preliminary Results of 39 Patients in a Placebo-Controlled, Long-Term Study

From the Department of Neurology and Psychiatry, General Hospital Linz, Linz, Austria.

Correspondence to Christian Lampl, MD, Department of Neurology and Psychiatry, General Hospital Linz, Krankenhausstrasse 9, 4020 Linz, Austria. E-mail christian.lampl{at}akh.linz.at

Abstract

Background and Purpose— We performed a double-blind, placebo-controlled study to investigate the effectiveness of amitriptyline for the prophylactic treatment of patients with acute thalamic stroke in preventing central poststroke pain.

Methods— Subject received, in a randomized sequence, either amitriptyline titrated from 10 to 75 mg in extended-release form or placebo over a therapy period of 365 days. We documented the time when pain developed; the intensity, type, site, and distribution of pain; and the presence/absence and type of allodynia.

Results— Thirty-nine patients (23 women and 16 men; age range, 36 to 68 years) with central poststroke pain participated. The placebo group showed a pain rate of 21% within 1 year after the diagnosis of thalamic stroke compared with 17% in the group under prophylactic treatment with amitriptyline. Average (SE) time to pain was 318 (23) days for patients in the placebo group and 324 (24) days for patients in the amitriptyline group.

Conclusions— With the achieved sample sizes of this study and a pain rate of approximately 21% in the placebo group, any near-perfect pain protection would have been detected. Near-perfect pain protection, in this context, refers to pain in <2.4% of the recruited patients treated with amitriptyline or in approximately 89% of placebo-treated patients. Larger studies are recommended to test the hypothesis that prophylactic amitriptyline reduces but does not completely prevent central poststroke pain.

Key Words: amitriptyline • antidepressive agents • cerebrovascular accident • pain • thalamic diseases

This article has been cited by other articles:

				B. Kumar, J. Kalita, G. Kumar, and U. K. Misra Central Poststroke Pain: A Review of Pathophysiology and Treatment Anesth. Analg., May 1, 2009; 108(5): 1645 - 1657. [Abstract] [Full Text] [PDF]